Carl Zeiss Meditec AG (OTCMKTS:CZMWY – Get Free Report)’s stock price fell 2.4% during mid-day trading on Thursday . The stock traded as low as $50.84 and last traded at $50.94. 1,805 shares were traded during trading, a decline of 56% from the average session volume of 4,099 shares. The stock had previously closed at $52.16.
Wall Street Analyst Weigh In
Several brokerages have recently issued reports on CZMWY. Barclays began coverage on shares of Carl Zeiss Meditec in a report on Tuesday, September 9th. They set an “overweight” rating for the company. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Carl Zeiss Meditec in a report on Tuesday, August 12th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold”.
Read Our Latest Report on Carl Zeiss Meditec
Carl Zeiss Meditec Stock Down 2.4%
About Carl Zeiss Meditec
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, such as ametropia (refraction), cataracts, glaucoma, and renital disorders.
Further Reading
- Five stocks we like better than Carl Zeiss Meditec
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally
- When to Sell a Stock for Profit or Loss
- Let the Good Times Roll: 2 Stocks Showing No Signs of Slowing
- Why Are These Companies Considered Blue Chips?
- Café Culture Revival? 3 Stocks to Watch After Chick-fil-A’s Move
Receive News & Ratings for Carl Zeiss Meditec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carl Zeiss Meditec and related companies with MarketBeat.com's FREE daily email newsletter.